Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
vivani | March 26, 2025
Read More
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
vivani | March 24, 2025
Read More
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
vivani | March 13, 2025
Read More
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
vivani | March 12, 2025
Read More
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
vivani | December 19, 2024
Read More
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
vivani | April 4, 2023
Read More
Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
vivani | March 31, 2023
Read More
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
vivani | March 21, 2023
Read More
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
vivani | November 14, 2022
Read More
Vivani Medical to Present at the ThinkEquity Investor Conference
vivani | November 14, 2022
Read More
Blog Navigation
Contact Us
To learn more about Vivani or LIBERATE-1, the upcoming First-in-Human trial of our long-term GLP-1 implant, please fill out the form.